Cognition Therapeutics (NASDAQ:CGTX) Given “Outperform” Rating at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research report report published on Wednesday, Benzinga reports. They currently have a $9.00 price objective on the stock.

Cognition Therapeutics Price Performance

CGTX stock opened at $1.82 on Wednesday. The stock’s fifty day moving average price is $2.09 and its 200-day moving average price is $1.65. The company has a market cap of $70.98 million, a P/E ratio of -2.30 and a beta of 1.67. Cognition Therapeutics has a 1 year low of $0.90 and a 1 year high of $3.49.

Hedge Funds Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CGTX. Pathstone Holdings LLC purchased a new position in shares of Cognition Therapeutics during the 4th quarter worth $4,080,000. Vanguard Group Inc. lifted its position in shares of Cognition Therapeutics by 465.7% during the 3rd quarter. Vanguard Group Inc. now owns 401,203 shares of the company’s stock valued at $762,000 after buying an additional 330,283 shares in the last quarter. Worth Venture Partners LLC bought a new position in shares of Cognition Therapeutics during the 1st quarter valued at approximately $473,000. Mercer Global Advisors Inc. ADV increased its holdings in Cognition Therapeutics by 721.0% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 130,951 shares of the company’s stock worth $242,000 after acquiring an additional 115,000 shares in the last quarter. Finally, Twin Focus Capital Partners LLC purchased a new stake in Cognition Therapeutics in the 4th quarter worth approximately $173,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.